DTC in the Crosshairs on the Hill

The House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations held a hearing this morning entitled "Direct-to-Consumer Advertising:  Marketing, Education or Deception?"  This is further evidence that as the election cycle heats up the Congress is quite likely to endorse legislation that would fundamentally change DTC and other pharmaceutical marketing practices, and that the scrutiny of same will endure for months to come.

The witness list included Dr. Ruth S. Day, Director Medical Cognition Laboratory at Duke University and a former member of the FDA’s Drug Safety and Risk Management Advisory Committee, as well as representation from the American Medical Association, the Kaiser Family Foundation, the Government Accountability Office, as well as several members of industry.

It is a gloomy day in Washington, and I expect a bit stormy up on the Hill. 

Share this:
Share this page via Email Share this page via Stumble Upon Share this page via Digg this Share this page via Facebook Share this page via Twitter
This entry was posted in DTC Advertising. Bookmark the permalink.

One Response to DTC in the Crosshairs on the Hill

Comments are closed.